Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive

    COVID-19 mild to moderate meta-analysis

    CORIMUNO-19, 2020
     
    NCT04331808
    RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
    64/67 inconclusive

      COVID-19 severe or critically meta-analysis

      REMAP-CAP tocilizumab, 2021
       
      NCT02735707
      RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
      353/402 conclusif
      • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
      • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).